The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. | High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer